Phil Nadeau
Stock Analyst at TD Cowen
(4.71)
# 716
Out of 4,478 analysts
793
Total ratings
54.2%
Success rate
12.2%
Average return
Main Sectors:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTX Nkarta | Initiated Coverage: Buy | n/a | $3.22 | - | 1 | Jun 23, 2026 | |
| VYGR Voyager Therapeutics | Maintained: Buy | n/a | $3.78 | - | 41 | Jun 17, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $130 | $114.17 | +13.87% | 36 | Jun 17, 2026 | |
| ELVN Enliven Therapeutics | Maintained: Buy | n/a | $49.82 | - | 17 | Jun 11, 2026 | |
| IPSC Century Therapeutics | Maintained: Buy | n/a | $2.43 | - | 4 | Jun 8, 2026 | |
| CABA Cabaletta Bio | Maintained: Buy | n/a | $3.19 | - | 15 | Jun 3, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | $120 | $58.99 | +103.42% | 83 | May 21, 2026 | |
| BIIB Biogen | Maintained: Buy | $215 | $216.12 | -0.52% | 52 | May 14, 2026 | |
| KURA Kura Oncology | Maintained: Buy | n/a | $11.10 | - | 21 | May 12, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Buy | n/a | $18.95 | - | 19 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $7.74 | - | 13 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $10.04 | - | 20 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $5.46 | - | 18 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $24.92 | - | 2 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $200 | $174.26 | +14.77% | 56 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $525 | $528.04 | -0.58% | 85 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.65 | - | 27 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $21.82 | - | 20 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $17.09 | - | 6 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $43.00 | - | 29 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $11.65 | n/a | 18 | Mar 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 27 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $30.39 | n/a | 31 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.89 | n/a | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $14.00 | n/a | 3 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $80 → $75 | $131.27 | n/a | 44 | Feb 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $13.09 | n/a | 12 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.08 | n/a | 7 | Aug 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $3.84 | n/a | 6 | Feb 26, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $385 | $654.27 | n/a | 40 | Feb 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.26 | n/a | 14 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2 → $16 | $0.000002 | n/a | 14 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $205 | $374.15 | n/a | 1 | Jul 26, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.32 | n/a | 1 | May 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $185 | $555.91 | n/a | 5 | Apr 28, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $19.28 | n/a | 1 | Aug 7, 2015 |
Nkarta
Jun 23, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $3.22
Upside: -
Voyager Therapeutics
Jun 17, 2026
Maintained: Buy
Price Target: n/a
Current: $3.78
Upside: -
Rhythm Pharmaceuticals
Jun 17, 2026
Maintained: Buy
Price Target: $130
Current: $114.17
Upside: +13.87%
Enliven Therapeutics
Jun 11, 2026
Maintained: Buy
Price Target: n/a
Current: $49.82
Upside: -
Century Therapeutics
Jun 8, 2026
Maintained: Buy
Price Target: n/a
Current: $2.43
Upside: -
Cabaletta Bio
Jun 3, 2026
Maintained: Buy
Price Target: n/a
Current: $3.19
Upside: -
BioMarin Pharmaceutical
May 21, 2026
Maintained: Buy
Price Target: $120
Current: $58.99
Upside: +103.42%
Biogen
May 14, 2026
Maintained: Buy
Price Target: $215
Current: $216.12
Upside: -0.52%
Kura Oncology
May 12, 2026
Maintained: Buy
Price Target: n/a
Current: $11.10
Upside: -
MoonLake Immunotherapeutics
May 11, 2026
Maintained: Buy
Price Target: n/a
Current: $18.95
Upside: -
May 11, 2026
Maintained: Buy
Price Target: n/a
Current: $7.74
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $10.04
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $5.46
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $24.92
Upside: -
May 5, 2026
Maintained: Buy
Price Target: $200
Current: $174.26
Upside: +14.77%
May 5, 2026
Maintained: Buy
Price Target: $525
Current: $528.04
Upside: -0.58%
May 5, 2026
Maintained: Buy
Price Target: n/a
Current: $3.65
Upside: -
Apr 30, 2026
Maintained: Buy
Price Target: n/a
Current: $21.82
Upside: -
Apr 29, 2026
Maintained: Buy
Price Target: n/a
Current: $17.09
Upside: -
Mar 18, 2026
Maintained: Hold
Price Target: n/a
Current: $43.00
Upside: -
Mar 9, 2025
Maintained: Buy
Price Target: n/a
Current: $11.65
Upside: n/a
Nov 13, 2024
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Oct 31, 2024
Maintained: Buy
Price Target: n/a
Current: $30.39
Upside: n/a
Mar 22, 2024
Rated: Hold
Price Target: n/a
Current: $5.89
Upside: n/a
Feb 13, 2023
Downgraded: Hold
Price Target: n/a
Current: $14.00
Upside: n/a
Feb 4, 2021
Maintained: Buy
Price Target: $80 → $75
Current: $131.27
Upside: n/a
Nov 9, 2020
Reiterated: Buy
Price Target: n/a
Current: $13.09
Upside: n/a
Aug 7, 2019
Maintained: Buy
Price Target: n/a
Current: $2.08
Upside: n/a
Feb 26, 2019
Initiated Coverage: Buy
Price Target: n/a
Current: $3.84
Upside: n/a
Feb 6, 2019
Rated: Hold
Price Target: $385
Current: $654.27
Upside: n/a
Jan 17, 2019
Maintained: Hold
Price Target: n/a
Current: $3.26
Upside: n/a
Nov 2, 2018
Maintained: Buy
Price Target: $2 → $16
Current: $0.000002
Upside: n/a
Jul 26, 2018
Rated: Buy
Price Target: $205
Current: $374.15
Upside: n/a
May 3, 2016
Reiterated: Hold
Price Target: n/a
Current: $2.32
Upside: n/a
Apr 28, 2016
Reiterated: Buy
Price Target: $185
Current: $555.91
Upside: n/a
Aug 7, 2015
Reiterated: Hold
Price Target: n/a
Current: $19.28
Upside: n/a